99
Views
0
CrossRef citations to date
0
Altmetric
Research Article

HIVEP3 as a potential prognostic factor promotes the development of acute myeloid leukemia

, , &
Pages 43-56 | Received 11 Sep 2022, Accepted 05 Dec 2022, Published online: 26 Dec 2022
 

Abstract

Acute myeloid leukemia (AML) is a common malignancy worldwide. Human immune deficiency virus type 1 enhancer-binding protein 3 (HIVEP3) was verified to play a vital role in types of cancers. However, the functional role of HIVEP3 in AML was rarely reported. In this study, CCK-8, colony formation assay, flow cytometry, and Trans-well chamber experiments were applied for detecting cell proliferation, apoptosis, and invasion in AML cells. The expression of proteins related to TGF-β/Smad signaling pathway was determined by western blot. Our data showed that the expression level of HIVEP3 was closely related to the risk classification and prognosis of AML patients. Moreover, HIVEP3 was highly expressed in AML patients and cells. Knockdown of HIVEP3 significantly repressed cell proliferation invasion, and enhanced cell apoptosis in HL-60 and THP-1 cells. In addition, HIVEP3 donwreglation could inhibit the TGF-β/Smad signaling pathway. TGF-β overexpression could reverse the inhibition effects of HIVEP3 knockdown on AML development and the TGF-β/Smad signaling pathway. These findings indicated that HIVEP3 contributed to the progression of AML via regulating the TGF-β/Smad signaling pathway and had a prognostic value for AML.

Disclosure statement

The authors declare that they have no competing interests.

Author contributions

YFT and YZZ designed the experiments; YFT, GGX, BH, and YZZ performed the laboratory work; YFT and YZZ wrote the manuscript. All authors were involved in analyzing the data and/or providing editorial comments/corrections to the final article.

Additional information

Funding

This work was financially supported by the Sci-Tech Planning Project of Jiaxing (Number: 2020AD30115 to ZYZ).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.